Clinical Trials Directory

Trials / Conditions / Respiratory Syncytial Viruses

Respiratory Syncytial Viruses

16 registered clinical trials studyying Respiratory Syncytial Viruses.

StatusTrialSponsorPhase
Active Not RecruitingEffectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western
NCT06813872
Pfizer—
Active Not RecruitingA Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Dis
NCT06077968
Pfizer—
CompletedA Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vacc
NCT05966090
GlaxoSmithKlinePhase 3
CompletedA Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
NCT05712460
PfizerPhase 1
CompletedA Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Resp
NCT04908683
Janssen Vaccines & Prevention B.V.Phase 3
CompletedPhase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participa
NCT04086472
Merck Sharp & Dohme LLCPhase 2
CompletedA Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-5371867
NCT04068792
Janssen Research & Development, LLCPhase 2
TerminatedA Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction
NCT03982199
Janssen Vaccines & Prevention B.V.Phase 2
CompletedA Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (A
NCT03303625
Janssen Vaccines & Prevention B.V.Phase 1 / Phase 2
TerminatedA Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of O
NCT03333317
Janssen Research & Development, LLCPhase 2
CompletedSafety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Alu
NCT03026348
NovavaxPhase 2
TerminatedStudy to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Ora
NCT02935673
Janssen Research & Development, LLCPhase 2
CompletedA Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in He
NCT02561871
Crucell Holland BVPhase 1
CompletedThe Respiratory Protection Effectiveness Clinical Trial
NCT01249625
Johns Hopkins UniversityN/A
CompletedIncidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian Children
NCT00585481
Abbott—
CompletedTGV:Use of the Quick Diagnostic Test of the Influenza and the Infection With RSV by the Paediatric Emergency U
NCT00263900
University Hospital, RouenN/A